Новости за 17.12.2024

Status: Confirmed Transaction
Date: 12/17/2024
Player: Marco Costantini (G)
From: Indy Fuel
To: Asiago
Source: You need a free account to view Transfer URL Sign In/Up

Status: Confirmed Transaction
Date: 12/17/2024
Player: Kevin He (F)
From: Niagara IceDogs
To: Winnipeg Jets
Information: Entry Level
Source: You need a free account to view Transfer URL Sign In/Up

This Viewpoint discusses new pathways for researchers to seek collaboration when conducting studies on treatments for rare diseases and conditions.

This Viewpoint discusses helping dual-eligible beneficiaries navigate Medicare and Medicaid coverage options.

This Viewpoint discusses the need to address all forms of AI-generated medical disinformation, regardless of whether it involves impersonating real or fictional professionals, medical societies, or research institutions, and the part that the Federal Trade Commission can play in achieving that goal.

This work discusses unfettering methadone from outdated regulations to empower patients to access treatment and advocate for methadone's expansion in their local communities by working with pharmacies and local health systems.

This cohort study aims to determine whether patient to nurse or patient to social worker staff ratios are associated with access to kidney transplant for adolescents and young adults.

This narrative review explores treatment with surgical aortic valve replacement vs transcatheter aortic valve implantation in older adults with severe symptomatic calcific aortic stenosis, including the type and timing of valve replacement.

This randomized cluster trial examines whether thrice-weekly symptom screening with symptom feedback and management care pathways, compared with usual care, improves overall self-reported symptoms in pediatric patients with cancer.

Over the past 5 decades, clinical outcomes have significantly improved for children with cancer through the availability of new treatment regimens. However, these advancements come with treatment-related symptomatic toxicities such as nausea, fatigue, and pain that often go undetected by care teams, leading to preventable suffering and avoidable downstream consequences such as hospitalizations.

In Reply We appreciate the interest in the Bisoprolol in COPD Study (BICS) from Drs Hsu and Lai. This was a pragmatic study to investigate the effect of bisoprolol on exacerbations in patients with COPD in the UK National Health Service, with any subgroup analysis considered exploratory and hypothesis generating. Moreover, the interpretation of any subgroup analyses in BICS is particularly limited because study recruitment was curtailed by the COVID-19 pandemic.

To the Editor We read with great interest the recent randomized clinical trial assessing the effect of bisoprolol in patients with chronic obstructive pulmonary disease (COPD) who are at high risk for exacerbation. The study found that bisoprolol did not reduce the number of self-reported COPD exacerbations requiring oral corticosteroids, antibiotics, or both. Although the study provides valuable insights, we would like to express some concerns about the findings.

This study compares differences in caregiver-reported hospice quality across categories of ownership, including for-profit private equity firm (PEF)/publicly traded company (PTC)–owned and non-PEF/PTC–owned hospices as well as not-for-profit–owned hospices.

This phase 2 randomized clinical trial evaluates the optimal dose, dosing interval, and safety of zerlasiran, a small-interfering RNA targeting hepatic synthesis of apolipoprotein(a), to treat patients with atherosclerotic cardiovascular disease and elevated lipoprotein(a) concentration.

Passport stored in a basket, I press my face to a halo pillow so someone will touch and touch me. I wait within a synthetic cadence of ocean waves’ crescendos. The body is a lonely crossroads. At first you only hover, flutter. Then you lash and drub me like the sea. Your oiled hands stretch and strain. Your joints pass bone to bore into muscle. You keep me close to whimpers. For this I paid, but not so dearly. To see your eyes would be a violation, though I can’t say why. I feel your work is tougher than mine... Читать дальше...

In Reply We appreciate the comments provided by Drs Lin and Huang. In theory, randomized trials could generate unbiased estimates of donor risk; however, randomized trials of living kidney donation are not ethically feasible. The best possible approach is to conduct a multicenter prospective cohort study that enrolls donors and nondonors with similar indicators of baseline health and follows them with minimal loss to follow-up for outcomes. We conducted such a study to produce estimates of kidney... Читать дальше...

To the Editor A recent study reported no significant difference in the risk of hypertension and albuminuria among living kidney donors and nondonors over a median follow-up of 7.3 years. In their Editorial, Drs Lorenz and Winkelmayer outlined some limitations of this study, and we have some additional concerns about the results.

This cross-sectional study evaluates trends and factors associated with selecting active surveillance or watchful waiting among individuals with intermediate-risk prostate cancer.

This JAMA Insights illustrates how explanatory communication strategies can help improve patient comprehension, including adherence to treatment recommendations and self-management.

In this narrative medicine essay, an emeritus professor of otolaryngology resists offering an affirmative response to a deceptively simple question about a complex reality.

This JAMA Patient Page describes common causes of accidental poisoning, risk reduction, and what to do in case of an accidental poisoning.

This study examines the characteristics of academic researchers who obtained US government–linked drug patents.

Studies that link coronary heart disease (CHD) to the status of health during childhood concentrate on three main areas: (1) elevated levels of cholesterol and triglicerides, even in infancy, (2) genetic inclination to CHD in children of CHD victims, and (3) histological differences in the structure of the coronary vessel wall in children of families with higher or lower incidence of CHD.

This Medical News article is an interview with FDA Commissioner Robert Califf, MD, about the agency’s regulatory powers over artificial intelligence tools for use in health care and biomedicine.

This Medical News article discusses XEC, the new SARS-CoV-2 “variant under monitoring” that’s gaining ground around the world.